SAFETY AND FEASIBILITY OF ARGATROBAN, RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR AND INTRA-ARTERIAL THERAPY IN STROKE (ARTSS-IA STUDY)

BACKGROUND AND OBJECTIVES: A randomized trial of concurrent recombinant tissue-type plasminogen activator (r-tPA) + thrombin-inhibition with Argatroban in stroke patients recently demonstrated safety and signal of efficacy compared to r-tPA alone, but patients having endovascular therapy (EVT) were...

Full description

Saved in:
Bibliographic Details
Published in:J Stroke Cerebrovasc Dis
Main Authors: Berekashvili, Ketevan, Soomro, Jazba, Shen, Loren, Misra, Vivek, Chen, Peng, Blackburn, Spiros, Dannenbaum, Mark, Grotta, James, Barreto, Andrew
Format: Artigo
Language:Inglês
Published: 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6252138/
https://ncbi.nlm.nih.gov/pubmed/30249518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2018.08.036
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items